This event has passed. ×

  • Friday, December 1, 2017
  • 1:30 PM–2:30 PM
  • Science Building 010

Benjamin K Johnson, Ph.D., Bioinformatics Research Scientist Bioinformatics & Biostatistics Core, Van Andel Research Institute

The ability to probe and understand disease progression has been revolutionized through high-throughput DNA and RNA sequencing technologies. Next- and third-generation sequencing approaches are accelerating biological discoveries and positively impacting patients in the clinic. For instance, Mycobacterium tuberculosis (TB) infections remain a global threat to public health. The current approach to treat TB infections requires that a person undergoing treatment takes a multi-drug regimen for 6-9 months and if not taken for the full course, may lead to disease relapse and drug resistance. Treating drug-resistant TB requires a multi-drug regimen to be taken for more than two years. Thus, we need faster acting antibiotics. We have leveraged high-throughput screening and sequencing approaches to identify a vulnerability during TB infection that can be exploited to develop new therapies against the disease. Additionally, I will highlight an example of how computational biology can complement personalized medicine to identify treatable targets of rare disease.

December 2017
Sun Mon Tue Wed Thu Fri Sat

View Today
Event quick search
Share this event
Add to calendar